DexCom DXCM received a warning letter from the FDA on March 4, 2025, following inspections of its San Diego and Mesa facilities in 2024. The FDA cited deficiencies in the company’s manufacturing ...

DexCom showed strong growth, margin expansion, and Stelo's OTC launch unlocked new markets despite competitive and regulatory ...

DexCom, Inc. DXCM is scheduled to release second-quarter 2024 results on Jul 25, after the closing bell. In the last reported quarter, the company’s earnings beat estimates by 18.52%. The bottom line ...

Dexcom has launched a generative AI platform aimed at providing personalized lifestyle tips to the users of its over-the-counter wearable glucose biosensor. The company said the feature has begun ...

DexCom's stock has declined 35% since my last bearish article, validating my "Sell" rating, though past bearish calls were incorrect as the stock previously doubled and tripled. Q3 results showed ...

Abbott and Dexcom have agreed to settle all of their remaining international legal disputes over patents related to their continuous glucose monitors for people with diabetes—just weeks after a ...